WS

West Pharmaceutical Services IncNYSE WST Stock Report

Last reporting period 30 Sep, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

22.467

Large

Exchange

XNYS - New York Stock Exchange, Inc

WST Stock Analysis

WS

Neutral

Based on Eyestock quantitative analysis, WST`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

99/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-4.6 %

Overvalued

Market cap $B

22.467

Dividend yield

0.25 %

Shares outstanding

74.135 B

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. The company is headquartered in Exton, Pennsylvania and currently employs 10,700 full-time employees. The firm operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment solutions, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

View Section: Eyestock Rating